3D Fallopian Tube Epithelium Organoid Model for Ovarian Cancer Research
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro models fail to accurately recapitulate the tissue-specific architecture of fallopian tube epithelium, hindering the understanding of high-grade serous carcinoma (HGSC) initiation and progression, and there is a need for relevant human models to study early alterations and develop effective biomarkers and treatments for ovarian cancer.
Innovation Solution
A method is developed to generate iPSC-derived 3D fallopian tube epithelium organoids by culturing human pluripotent stem cells with specific growth factors and kinase inhibitors, allowing for the differentiation into Mullerian epithelium cells and subsequent formation of organoids that mimic the convoluted luminal structure of the fallopian tube, enabling the study of early disease mechanisms and drug responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional in vitro models are used, then simplicity and ease of culture are maintained, but tissue-specific architecture and early disease alterations cannot be accurately recapitulated
Solution Approach 1:
The differentiation process is divided into distinct temporal stages (Days 0-2, 2-4, 4-6, 6-8) with specific growth factors and conditions for each stage, allowing progressive formation of tissue architecture from pluripotent stem cells through intermediate mesoderm to Mullerian epithelium
Solution Approach 2:
The patent transitions from traditional 2D monolayer cultures to 3D organoid formation by culturing cells in Matrigel matrix, enabling the self-organization of Fallopian tube epithelium with convoluted luminal structures that accurately mimic in vivo tissue architecture
2Reliability
If complex differentiation protocols with multiple growth factors and inhibitors are used, then accurate FTE organoid formation is achieved, but culture conditions and process complexity increase
Solution Approach 1:
The protocol pre-specifies the temporal sequence of growth factor additions and withdrawals (Activin A on Days 0-2, BMP4 on Days 2-4, WNT4 on Days 4-6) and inhibitor applications (CHIR99021, Y-27632, IWR-1-endo) to guide cells through deterministic differentiation stages, ensuring reliable organoid formation
Solution Approach 2:
The differentiation protocol systematically changes chemical parameters including growth factor concentrations, inhibitor dosages, and media compositions at defined time points to drive cellular transitions from pluripotent state through intermediate mesoderm to mature Fallopian tube epithelium
Data Source
AI summary
The fallopian tube epithelium (FTE) has been recognized as a site of origin of high-grade serous ovarian cancer (HGSC). However, absence of relevant in vitro human models that can recapitulate tissue-specific architecture has hindered understanding of FTE transformation and initiation of HGSC. Here, induced pluripotent stem cells (iPSCs) were used to establish a novel 3-dimensional (3D) human FTE organoid in vitro model containing the relevant cell types of the human fallopian tube as well as a luminal architecture that closely reflects the organization of fallopian tissues in vivo. Modulation of Wnt and nodal/activin signaling pathways provided iPSC differentiation into Müllerian cells and subsequent use of pro-Müllerian growth factors promoted FTE precursors. The expression of Müllerian markers verified correct cellular differentiation. An innovative 3D growth platform, which enabled the FTE organoid to self-organize into a convoluted luminal structure, permitted final differentiation to a FTE lineage. This powerful human-derived FTE organoid model can be used to study the earliest stages of HGSC development and to identify novel and specific biomarkers of early fallopian tube epithelial cell transformation.